Related references
Note: Only part of the references are listed.Assessment of chemotherapy on various biochemical markers in breast cancer patients
Marcia F. C. J. Paz et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer
B. E. P. J. Vriens et al.
EUROPEAN JOURNAL OF CANCER (2013)
A pilot study: Application of hemoglobin and cortisol levels, and a memory test to evaluate the quality of life of breast cancer patients on chemotherapy
Wings T. Y. Loo et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2013)
Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer
Anne F. Schott et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer
Jiannan Wu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Subtypes of breast cancer show preferential site of relapse
Marcel Smid et al.
CANCER RESEARCH (2008)
Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry
Katrina R. Bauer et al.
CANCER (2007)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
V Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer
L Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
RJ Burcombe et al.
BRITISH JOURNAL OF CANCER (2005)
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27
HD Bear et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy
U Denison et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741
ML Citron et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up
JG Schrama et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
